Apologies, I meant not even close to Ph2 clinical trials which is why IMU only presented the completion of Ph2 clinical trials this year at the last conference so they weren't even close to commercialisation a few years ago you were talking about but ideal for a T/O bid.
Clearly the MC was overvalue at that stage of the clinical trial for the one product but a poster mentioned there was a "rumour" T/O bid at $1 which likely caused the buying but $6B for only HER-Vaxx doesn't sound right even had the product completed Ph3 clinical trials and received FDA approval which was what I meant by needing more clinical data. I still think there's a market for HER-Vaxx but alone it won't be worth $6B.
Apologies, I meant not even close to Ph2 clinical trials which...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.8¢ |
Change
-0.001(1.45%) |
Mkt cap ! $497.7M | |||
| Open | High | Low | Value | Volume |
| 6.9¢ | 7.0¢ | 6.7¢ | $1.242M | 18.24M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 1443066 | 6.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.9¢ | 671816 | 6 |
View Market Depth
| Last trade - 16.10pm 29/05/2024 (20 minute delay) ? |
|
|||||
|
Last
6.9¢ |
Change
-0.001 ( 0.72 %) |
||||
| Open | High | Low | Volume | ||
| 6.9¢ | 6.9¢ | 6.7¢ | 6493774 | ||
| Last updated 15.59pm 29/05/2024 ? | |||||
| IMU (ASX) Chart |